MA66139B1 - Formulations d'un modulateur de somatostatine - Google Patents

Formulations d'un modulateur de somatostatine

Info

Publication number
MA66139B1
MA66139B1 MA66139A MA66139A MA66139B1 MA 66139 B1 MA66139 B1 MA 66139B1 MA 66139 A MA66139 A MA 66139A MA 66139 A MA66139 A MA 66139A MA 66139 B1 MA66139 B1 MA 66139B1
Authority
MA
Morocco
Prior art keywords
pharmaceutically acceptable
tablet
spray
formulations
solid dispersion
Prior art date
Application number
MA66139A
Other languages
English (en)
French (fr)
Inventor
Gerald Burke
Ian Yates
Hannah Bulovsky
Kyle Kyburz
Clayton Tyler
Original Assignee
Crinetics Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals, Inc. filed Critical Crinetics Pharmaceuticals, Inc.
Publication of MA66139B1 publication Critical patent/MA66139B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA66139A 2020-09-09 2021-09-07 Formulations d'un modulateur de somatostatine MA66139B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063076024P 2020-09-09 2020-09-09
PCT/US2021/049282 WO2022055880A1 (en) 2020-09-09 2021-09-07 Formulations of a somatostatin modulator
EP21786673.0A EP4210700B1 (en) 2020-09-09 2021-09-07 Formulations of a somatostatin modulator

Publications (1)

Publication Number Publication Date
MA66139B1 true MA66139B1 (fr) 2025-09-30

Family

ID=78078387

Family Applications (1)

Application Number Title Priority Date Filing Date
MA66139A MA66139B1 (fr) 2020-09-09 2021-09-07 Formulations d'un modulateur de somatostatine

Country Status (27)

Country Link
US (3) US11266641B1 (https=)
EP (2) EP4210700B1 (https=)
JP (2) JP7796115B2 (https=)
KR (1) KR20230066379A (https=)
CN (2) CN116456968B (https=)
AR (1) AR123453A1 (https=)
AU (1) AU2021341936A1 (https=)
CA (1) CA3191084A1 (https=)
CL (1) CL2023000627A1 (https=)
CO (1) CO2023004346A2 (https=)
DK (1) DK4210700T3 (https=)
ES (1) ES3040117T3 (https=)
FI (1) FI4210700T3 (https=)
HR (1) HRP20250995T1 (https=)
IL (1) IL301038A (https=)
LT (1) LT4210700T (https=)
MA (1) MA66139B1 (https=)
MD (1) MD4210700T2 (https=)
MX (1) MX2023002761A (https=)
PE (1) PE20231850A1 (https=)
PL (1) PL4210700T3 (https=)
PT (1) PT4210700T (https=)
RS (1) RS67208B1 (https=)
SI (1) SI4210700T1 (https=)
SM (1) SMT202500315T1 (https=)
WO (1) WO2022055880A1 (https=)
ZA (1) ZA202303250B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL264178B2 (en) 2016-07-14 2024-05-01 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
CA3191084A1 (en) 2020-09-09 2022-03-17 Gerald Burke Formulations of a somatostatin modulator
WO2023137018A1 (en) * 2022-01-11 2023-07-20 Crinetics Pharmaceuticals, Inc. Uses of a somatostatin modulator for the treatment of carcinoid syndrome
PE20260136A1 (es) * 2022-05-11 2026-01-21 Lilly Co Eli Composiciones farmaceuticas de glp1
CN115919866A (zh) * 2022-12-07 2023-04-07 深圳海王医药科技研究院有限公司 特泊替尼固体分散体及其制备方法
KR20250162795A (ko) 2023-03-28 2025-11-19 크리네틱스 파마슈티칼스, 인크. 간 기능장애가 있는 환자에게 팔투소틴을 투여하기 위한 조성물 및 방법
JP7797570B2 (ja) 2023-05-23 2026-01-13 ユルチョン・ケミカル・カンパニー・リミテッド セルパウチ用フィルム及びその保管方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
CA2468159A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
WO2003066055A1 (en) 2002-02-04 2003-08-14 F. Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
US7767817B2 (en) 2003-09-05 2010-08-03 Binghe Wang Water soluble boronic acid fluorescent reporter compounds and methods of use thereof
JP2008506695A (ja) 2004-07-13 2008-03-06 グラクソ　グループ　リミテッド 抗細菌剤
US20060183763A1 (en) 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
WO2007098214A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
WO2007103554A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
AU2007309708A1 (en) 2006-03-13 2008-05-02 Merck Sharp & Dohme Corp. Somatostatin agonists
US8871728B2 (en) 2007-06-29 2014-10-28 Georgia Tech Research Corporation Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof
HRP20180328T1 (hr) * 2008-08-13 2018-04-20 Vertex Pharmaceuticals Inc. FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
US20100256184A1 (en) * 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) * 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
JP5564045B2 (ja) 2008-09-02 2014-07-30 ノバルティス アーゲー 二環式キナーゼ阻害剤
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
CA2806332C (en) 2010-07-30 2017-11-14 Oncotherapy Science, Inc. Quinoline derivatives and melk inhibitors containing the same
RU2013113627A (ru) * 2010-08-27 2014-10-10 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
US9328075B2 (en) 2011-05-05 2016-05-03 St. Jude Children's Research Hospital Pyrimidinone compounds and methods for treating influenza
RU2637936C2 (ru) 2011-05-23 2017-12-08 Элан Фармасьютикалз, Инк. Ингибиторы активности киназы lrrk2
WO2012163354A1 (en) 2011-05-31 2012-12-06 Linak A/S Actuator
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
DE102011113749A1 (de) 2011-09-14 2013-03-14 Aicuris Gmbh & Co. Kg Sulfonsäuresalze Heterocyclylamid-substituiertr Imidazole
US20140228417A1 (en) 2011-10-05 2014-08-14 Mapi Pharma Ltd. Process and intermediates for the preparation of substituted 2-arylthiazole carboxylic acids
WO2014007228A1 (ja) 2012-07-03 2014-01-09 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
KR20150039832A (ko) 2012-08-06 2015-04-13 사피라 파르마슈티칼즈 게엠베하 디하이드록시피리미딘 탄산 유도체 및 바이러스성 질환의 치료, 개선 또는 예방에서의 이의 용도
JP6404217B2 (ja) 2012-09-11 2018-10-10 メディベイション プロステイト セラピューティクス エルエルシー エンザルタミドの製剤
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
WO2014114575A1 (en) 2013-01-22 2014-07-31 F. Hoffmann-La Roche Ag Pharmaceutical composition with improved bioavailability
US10647664B2 (en) 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
US9643951B2 (en) 2013-09-30 2017-05-09 Ono Pharmaceutical Co., Ltd. Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JPWO2015146929A1 (ja) 2014-03-24 2017-04-13 武田薬品工業株式会社 複素環化合物
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
AU2015360485B2 (en) 2014-12-10 2020-06-25 Amryt Endo, Inc. Oral octreotide administered in combination with other therapeutic agents
US9957267B2 (en) 2015-07-01 2018-05-01 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
EP3317278B1 (en) 2015-07-01 2021-04-14 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
RS61645B1 (sr) 2015-10-30 2021-04-29 Neurocrine Biosciences Inc Valbenazin ditozilat i njihovi polimorfi
EP3374350B1 (en) 2015-11-09 2022-01-05 Forge Therapeutics, Inc. Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
PT3889145T (pt) 2015-12-17 2024-04-02 Merck Patent Gmbh 8-ciano-5-piperidino-quinolinas como antagonistas de tlr7/8 e suas utilizações para tratamento de distúrbios imunitários
MX2019000246A (es) 2016-07-07 2019-05-27 Plantex Ltd Formas en estado solido del dimesilato de palbociclib.
IL264178B2 (en) 2016-07-14 2024-05-01 Crinetics Pharmaceuticals Inc Somatostatin modulators and uses thereof
EP3596062A4 (en) 2017-03-16 2020-08-26 Crinetics Pharmaceuticals, Inc. SOMATOSTATIN MODULATORS AND THEIR USES
WO2018208987A2 (en) 2017-05-10 2018-11-15 Forge Therapeutics, Inc. Antibacterial compounds
CN110913840A (zh) 2017-08-11 2020-03-24 默克专利股份公司 包含3-氟-4-[7-甲氧基-3-甲基-8-(1-甲基-1H-吡唑-4-基)-2-氧代-2,3-二氢-咪唑并[4,5-c]喹啉-1-基]-苄腈的药物制剂
PT3740475T (pt) 2018-01-17 2022-07-18 Crinetics Pharmaceuticals Inc Processo de produção de moduladores da somatostatina
SMT202500155T1 (it) 2018-09-18 2025-05-12 Crinetics Pharmaceuticals Inc Modulatori della somatostatina e loro usi
JP2022540922A (ja) * 2019-07-17 2022-09-20 クリネティックス ファーマシューティカルズ，インク． ソマトスタチンモジュレーターの結晶形態
CA3191084A1 (en) 2020-09-09 2022-03-17 Gerald Burke Formulations of a somatostatin modulator
BR112023024465A2 (pt) 2021-05-25 2024-02-06 Crinetics Pharmaceuticals Inc Usos de um modulador de somatostatina para o tratamento de doença
CN117377473A (zh) * 2021-05-25 2024-01-09 克林提克斯医药股份有限公司 生长抑素调节剂用于治疗疾病的用途

Also Published As

Publication number Publication date
US20240398782A1 (en) 2024-12-05
AU2021341936A9 (en) 2025-03-20
AU2021341936A1 (en) 2023-05-25
HRP20250995T1 (hr) 2025-12-05
US11957674B2 (en) 2024-04-16
JP2026067866A (ja) 2026-04-21
US20220071986A1 (en) 2022-03-10
KR20230066379A (ko) 2023-05-15
CL2023000627A1 (es) 2023-09-01
SMT202500315T1 (it) 2025-11-10
FI4210700T3 (fi) 2025-09-16
MD4210700T2 (ro) 2025-11-30
DK4210700T3 (da) 2025-09-08
ES3040117T3 (en) 2025-10-28
ZA202303250B (en) 2025-08-27
CN121943816A (zh) 2026-05-01
CA3191084A1 (en) 2022-03-17
US20220143007A1 (en) 2022-05-12
JP2023540137A (ja) 2023-09-21
IL301038A (en) 2023-05-01
PL4210700T3 (pl) 2025-10-20
CN116456968B (zh) 2026-03-20
JP7796115B2 (ja) 2026-01-08
EP4635497A3 (en) 2025-11-19
WO2022055880A1 (en) 2022-03-17
RS67208B1 (sr) 2025-10-31
US11266641B1 (en) 2022-03-08
TW202227072A (zh) 2022-07-16
MX2023002761A (es) 2023-04-03
EP4210700B1 (en) 2025-08-06
EP4210700A1 (en) 2023-07-19
EP4635497A2 (en) 2025-10-22
AR123453A1 (es) 2022-11-30
PT4210700T (pt) 2025-09-01
LT4210700T (lt) 2025-10-10
PE20231850A1 (es) 2023-11-21
CN116456968A (zh) 2023-07-18
SI4210700T1 (sl) 2025-12-31
CO2023004346A2 (es) 2023-04-27

Similar Documents

Publication Publication Date Title
ZA202303250B (en) Formulations of a somatostatin modulator
US20220008426A1 (en) Therapeutic combinations comprising a c-raf inhibitor
US20220016059A1 (en) Methods for the treatment of bladder cancer
MX2025003420A (es) Compuesto de anillo fusionado con pirimidina, y su método de preparación y uso
NO20065638L (no) Formuleringer med kontrollert frigivelse inneholdende vardenafil
EP3219308A1 (en) Melt-extruded solid dispersions containing an apoptosis-inducing agent
Protopopova et al. In search of new cures for tuberculosis
WO2002092088A3 (en) Novel use of 2h-benzimidazol-2-one, 1,3-dihadro-1-(2{4-{3-(trifluoromethyl}phenyl]-1-piperazinyl}ethyl)- and its physiologically acceptable acid addition salts
MY208983A (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
US11648238B2 (en) Implantable isoxazoline pharmaceutical compositions and uses thereof
JP2019506387A5 (https=)
KR102640532B1 (ko) 신규한 테비페넴 피복실 속방형 및 변형 방출형 경구 투여형
JP2022553313A (ja) セレキシパグを含む医薬組成物
US20060099253A1 (en) Antibiotic product formulation
MX2026000979A (es) Una forma farmaceutica solida de dosificacion bucodispersable de safinamida
JP2016033123A (ja) 受容体の細胞内輸送制御による白血病治療のための新規医薬組成物
MX2021008321A (es) Composiciones farmaceuticas que comprenden (s)-4-(4-(4-(((2-(2,6-d ioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperaz in-1-il)-3-fluorobenzonitrilo y metodos para su uso.
WO2005058341A3 (en) Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
MX2025005061A (es) Formulaciones farmaceuticas orales que contienen derivados de 4-((2-hidroxi-3-metoxibenzil)amino)bencenosulfonamida
Guida et al. Everolimus versus Axitinib as second-line therapy in metastatic renal cell carcinoma: experience from institut gustave roussy
FI3600276T3 (fi) Betahistiini tai sen farmaseuttisesti hyväksyttävä suola ja monoamiinioksidaasin inhibiittori käytettäväksi yhden tai useamman huimausoireen hoitamisessa tai ehkäisemisessä kohteessa
Dacoll et al. An optimized clarithromycin-free 14-day triple therapy for Helicobacter pylori eradication achieves high cure rates in Uruguay
Tyson et al. New developments in the management of nonmuscle invasive bladder cancer
EP3496719B1 (en) A multi-class anti-retroviral composition
MX2023007710A (es) Formulacion de dispersion solida amorfa.